CytomX
CTMX
2.47
-0.09
-3.33%
CytomX
US · CTMX
#3678 by market cap
Listed 2015
2.47
-0.09
-3.33%
Live - 5344 symbols - heartbeat 367s ago
· 2026-10-08 10:11
Pre-market
2.62
+2.65%
After-hours
2.54
-0.39%
Overnight
2.63
+3.14%
- Market cap
- 537.12M
- P/E (TTM)i
- -4.32
- P/Bi
- 1.78
- EPSi
- -0.15
- Div yieldi
- 0.00%
- 52W posi
- 0%
Reader sentiment
Are you bullish or bearish on CTMX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 105.18% +0.09pp
- Institutions
- 201
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund49.73%
Hedge Fund28.30%
VC/PE Fund18.14%
Public Company8.31%
Individual/Insider0.57%
Government Pension Fund0.26%
Insurance Company0.18%
Private Company0.16%
Top holders as of 2026-06-30
FMR
15.01% · 32.71M sh
Kynam Capital Management, LP
9.96% · 21.70M sh
BlackRock
8.06% · 17.56M sh
Longitude Capital Management Co., LLC
7.02% · 15.29M sh
Bank of America Corporation
6.92% · 15.08M sh
State Street Global Advisors
5.39% · 11.75M sh
Perceptive Advisors LLC
4.79% · 10.44M sh
Vanguard Capital Management, LLC
4.49% · 9.79M sh
Point72 Asset Management, L.P.
3.58% · 7.81M sh
Wellington Management Group
2.37% · 5.17M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 40 buys · 10 sells
| Name | Role | Stake |
|---|---|---|
| Sean McCarthy | Chairperson & CEO | 0.37% |
| Marcia Belvin | Senior VP & Chief Scientific Officer | 0.08% |
| Christopher Ogden | Senior VP of Finance and Accounting, Principal Financial Officer & Principal Accounting Officer | 0.06% |
| Lloyd Rowland | Senior VP, General Counsel, Chief Compliance Officer & Secretary | 0.04% |
| Yu-Waye Chu | Chief Medical Officer | 0.02% |
| Elaine Jones | Independent Director | 0.00% |
| Mani Mohindru | Independent Director | -- |
| James Meyers | Independent Director | -- |
| Matthew Young | Lead Independent Director | -- |
| Halley Gilbert | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-02 | Alejandra Carvajal | Chief Legal Officer | Other Acquisition | +100,000 | -- |
| 2026-08-02 | Alejandra Carvajal | Chief Legal Officer | Other Derivative Acquisition | +450,000 | $3.17 |
| 2026-07-23 | Charles Fuchs | Former Independent Director | Other Derivative Acquisition | +118,000 | $3.24 |
| 2026-06-16 | Elaine Jones | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-16 | Mani Mohindru | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-16 | James Meyers | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-16 | Matthew Young | Lead Independent Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-16 | Halley Gilbert | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-16 | Alan Ashworth | Independent Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-16 | Zhen Su | Director | Other Derivative Acquisition | +59,000 | $2.96 |
| 2026-06-14 | Christopher Ogden | Senior VP of Finance and Accounting, Principal Financial Officer & Principal Accounting Officer | Open Market Disposition | -1,624 | $3.05 |
| 2026-03-16 | Sean McCarthy | Chairperson & CEO | Open Market Disposition | -118,969 | $6.42 |
| 2026-03-16 | Yu-Waye Chu | Chief Medical Officer | Open Market Disposition | -21,279 | $6.42 |
| 2026-03-16 | Marcia Belvin | Senior VP & Chief Scientific Officer | Open Market Disposition | -31,492 | $6.42 |
| 2026-03-16 | Christopher Ogden | Senior VP of Finance and Accounting, Principal Financial Officer & Principal Accounting Officer | Open Market Disposition | -19,323 | $6.42 |
| 2026-02-01 | Sean McCarthy | Chairperson & CEO | Other Acquisition | +210,000 | -- |
| 2026-02-01 | Sean McCarthy | Chairperson & CEO | Other Derivative Acquisition | +980,000 | $6.09 |
| 2026-02-01 | Rachael Lester | Chief Business Officer & Senior VP | Other Acquisition | +20,000 | -- |
| 2026-02-01 | Rachael Lester | Chief Business Officer & Senior VP | Other Derivative Acquisition | +50,000 | $6.09 |
| 2026-02-01 | Yu-Waye Chu | Chief Medical Officer | Other Acquisition | +75,000 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:11:05 · For reference only, not investment advice and not tailored to your situation.